DECS-II
Trial question
What is the role of high-dose dexamethasone in patients undergoing cardiac surgery?
Study design
Multi-center
Single blinded
RCT
Population
Characteristics of study participants
20.0% female
80.0% male
N = 1951
1951 patients (390 female, 1561 male).
Inclusion criteria: patients undergoing cardiac surgery.
Key exclusion criteria: poor language comprehension; T1DM; endocarditis or other evidence of sepsis; preoperative corticosteroids.
Interventions
N=undefined dexamethasone (at a dose of 1 mg/kg, maximum dose of 100 mg).
N=undefined standard care (no dexamethasone with standard care).
Primary outcome
Median number of home days
23 days
23.1 days
23.1 days
17.3 days
11.6 days
5.8 days
0.0 days
Dexamethasone
Standard
care
No significant
difference ↔
No significant difference in median number of home days (23 days vs. 23.1 days; MD 0.1, 95% CI -0.3 to 0.5).
Secondary outcomes
Significant decrease in median ICU stay (29 hours vs. 43 hours; MD -14, 95% CI -23.52 to -4.48).
Conclusion
In patients undergoing cardiac surgery, dexamethasone was not superior to standard care with respect to median number of home days.
Reference
Paul S Myles, Jan M Dieleman, Karin E Munting et al. Dexamethasone for Cardiac Surgery: A Practice Preference-Randomized Consent Comparative Effectiveness Trial. Anesthesiology. 2024 Jun 21. Online ahead of print.
Open reference URL